|
Back to Annual Meeting Program
Molecular Analysis of Prostate Core Biopsies Using Tissue Prints
Justin M. Zbrzezny, MD, Marc D. Manganiello, MD, William C. Faust, MD, Kai H. Hammerich, MD, John E. Humphrey, MD, Christina Deliyiannis, BS, John A. Libertino, MD, Antonia H. Holway, Phd, Kimberly M. Rieger-Christ, Phd.
Lahey Clinic Medical Center, Burlington, MA, USA.
BACKGROUND:The clinical management of patients with glandular atypia on prostate biopsy remains controversial. Since there is no way to predict which lesions are indolent and which will progress to cancer, a repeat biopsy at three months is currently the standard of care. The goal of this work is to identify biomarkers capable of defining this complex diagnosis.
METHODS:To overcome the issue of tissue availability, prints of TRUS prostate biopsies were collected by touching the core to nitrocellulose prior to fixation, leaving behind a layer of cells. RNA was extracted from the nitrocellulose and used for the analysis of a panel of microRNAs (miRNAs) by qRT-PCR. Tissue prints were analyzed from cores containing only benign tissue, atypical glands, or prostate cancer.
RESULTS:Differences in expression profiles were observed between benign, atypia, and cancer containing core prints for both novel and established prostate cancer markers. MiRNA-143 demonstrated significantly lower expression in cancer containing cores than benign cores. Interestingly, cores containing atypical glands represented a mixed population with some atypical cores expressing miRNA-143 levels consistent with the cancer containing cores and some atypical cores expressing miRNA-143 levels consistent with the benign cores. This suggests that miRNA-143 expression levels in tissue prints may provide predictive information when histological analysis of the core tissue is inconclusive.
CONCLUSIONS:This study validates the use of tissue printed samples to identify molecular markers of prostate cancer from core biopsies. Prostate cancer markers including miRNA-143 demonstrate differential expression between benign and cancer containing cores. By correlating this information with clinical course, our long-term goal is to develop novel tools to aid in the identification of patients with non-cancerous findings at high-risk to progress to prostate cancer.
Back to Annual Meeting Program
|
